Scholarlink

<p>Cyclin-E1 protein overexpression, including through <i>CCNE1</i> gene amplification, is recognized as a poor prognostic factor in high-grade serous ovarian cancer (HGSOC) and is a promising predictive marker for investigational therapies targeting cell-cycle checkpoints. However, the demonstration of its clinical utility remains elusive due to inconsistent definitions of protein overexpression and gene amplification. This study characterizes Cyclin-E1 overexpression and <i>CCNE1</i> amplification prevalence and prognostic value in HGSOC using both original and public clinical cohorts. Fifty-nine percent of tumors overexpressed Cyclin-E1, more than half of which had no evidence of <i>CCNE1</i> gene amplification. The prevalence of <i>CCNE1</i> amplification varied across studies and was higher in interventional studies. Patients with Cyclin-E1 positive tumors had poorer outcomes after adjuvant therapy. Platinum-based chemotherapy increased Cyclin-E1 expression. These patients were less likely to benefit from PARP inhibitors (75% are BRCA-wildtype) or mirvetuximab-soravtansine (67% were not FRα-high), highlighting a distinct patient population in need of novel therapies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Cyclin E1 overexpression identifies a therapeutically relevant poor prognostic patient subgroup in high-grade serous ovarian cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月30日

查看全文
  • Doris Kim,
  • Heekyung Chung,
  • Mona Abed,
  • Jianhui Ma,
  • Nandini Molden,
  • Changhwan Shim,
  • Divya Rajendran,
  • James Yen,
  • Jinkil Jeong,
  • Alexandra Levy,
  • Elisa Yaniz-Galende,
  • Felix Blanc-Durand,
  • Christophe Desauw,
  • Philippe Follana,
  • Nathalie Bonichon-Lamichhane,
  • Stéphane Oudard,
  • Véronique D’Hondt,
  • Céline Gavoille,
  • Danielle D. Jandial,
  • Funda Meric‑Bernstam,
  • Joyce F. Liu,
  • Fiona Simpkins,
  • Leslie M. Randall,
  • Alexandra Leary,
  • Mark R. Lackner,
  • Olivier Harismendy

摘要

Cyclin-E1 protein overexpression, including through CCNE1 gene amplification, is recognized as a poor prognostic factor in high-grade serous ovarian cancer (HGSOC) and is a promising predictive marker for investigational therapies targeting cell-cycle checkpoints. However, the demonstration of its clinical utility remains elusive due to inconsistent definitions of protein overexpression and gene amplification. This study characterizes Cyclin-E1 overexpression and CCNE1 amplification prevalence and prognostic value in HGSOC using both original and public clinical cohorts. Fifty-nine percent of tumors overexpressed Cyclin-E1, more than half of which had no evidence of CCNE1 gene amplification. The prevalence of CCNE1 amplification varied across studies and was higher in interventional studies. Patients with Cyclin-E1 positive tumors had poorer outcomes after adjuvant therapy. Platinum-based chemotherapy increased Cyclin-E1 expression. These patients were less likely to benefit from PARP inhibitors (75% are BRCA-wildtype) or mirvetuximab-soravtansine (67% were not FRα-high), highlighting a distinct patient population in need of novel therapies.